Drug intelligence / Profile preview

lapatinib + paclitaxel + trastuzumab

Development stage: Unknown
Lead developer: GSK
Modality: Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

This is a combination regimen used primarily in the treatment of HER2-positive breast cancer. Lapatinib is an orally-active small molecule kinase inhibitor targeting HER1 (EGFR) and HER2 (ERBB2), trastuzumab is a monoclonal antibody targeting HER2, and paclitaxel is a taxane chemotherapy agent that disrupts microtubule function to inhibit cell division. The combination has been studied in neoadjuvant, adjuvant, and metastatic settings for HER2-positive breast cancer to improve pathologic complete response rates and disease-free survival[1][6][8].

Other names: lapatinib/paclitaxel/trastuzumabpaclitaxel/trastuzumab/lapatinib

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on lapatinib + paclitaxel + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lapatinib + paclitaxel + trastuzumab.

Explore the full profile